High-Affinity Probes (HAPs) are engineered molecular tools designed for in situ detection and quantification of therapeutic binding sites on patient tumor tissue. They enable precise assessment of target accessibility, binding site density, and spatial distribution, providing critical insights for biomarker validation, patient stratification, and therapy optimization. HAPs are compatible with a wide range of therapeutics, including small molecules, monoclonal antibodies, bispecific antibodies, ADCs, radioligands, and CAR-T cell targets, making them versatile solutions for advancing precision oncology.
HAPs integrate seamlessly into various workflows, from preclinical drug development to exploratory clinical research, supporting applications such as drug-target interaction mapping, patient stratification, and therapy exploration for challenging cases. The technology enhances precision in oncology research by delivering actionable molecular insights that drive innovation across the drug development pipeline.
Our Custom Probe Development Service delivers tailored High-Affinity Probes (HAPs) for detecting therapeutic binding sites of your drug of interest. These custom-designed probes support pharmaceutical and biotech companies throughout the drug development process, from preclinical research to clinical trials.
With end-to-end solutions and rapid timelines, this service enables precise in situ quantification of drug-target interactions, helping to optimize molecular designs, patient selection, and trial outcomes.
The HAP Clinical Trial Stratification Service uses High-Affinity Probes to stratify patients in clinical trials based on the accessibility and density of therapeutic binding sites in their tumor tissues.
This service enhances clinical trial quality by identifying patients with optimal tumor profiles, enabling the exploration of predictive biomarkers and enriching trial populations for therapies like ADCs, monocloncal antibodies, bispecific antibodies, radioligands and small molecules.
Our HAP-Based Drug Repurposing and Cross-Tumor Affinity Screening Service evaluates the binding affinity of investigational or approved drugs across diverse tumor types.
By uncovering new therapeutic opportunities or assessing off-target effects, this service helps drug developers explore repurposing strategies, reduce trial risks, and expand the therapeutic reach of existing assets.
The Patient-Specific Drug Affinity Profiling service leverages High-Affinity Probes to test drug binding on patient-derived tumor tissue, providing molecular insights into potential treatment options for challenging oncology cases.
While designed for research purposes, this service enables oncologists to explore personalized therapy pathways and supports precision oncology approaches in patients with limited treatment options.
We invite you to connect with us to explore how our High-Affinity Probe (HAP) technology can address your research and clinical objectives. Whether your focus is on custom probe development, enhancing clinical trial strategies, or advancing therapeutic profiling, our team is ready to provide tailored support and expert guidance.
Contact us to discuss your specific needs, request detailed information, or learn more about how HAP technology can contribute to your success in drug development and precision oncology.
